Company Overview
LeonaBio, Inc., operating under the ticker ATHA, is a clinical-stage biopharmaceutical company dedicated to developing small molecules designed to restore neuronal health and slow neurodegradation. This entity functions within the Healthcare sector and the Biotechnology industry, a space characterized by high capital requirements and significant risk associated with bringing novel therapies from the laboratory to market approval. The company maintains a market capitalization of $26.62M and employs a workforce of 26 individuals to execute its research and development initiatives. These financial figures indicate that the organization operates at a relatively small scale typical of early-stage biotechnology firms that are prioritizing pipeline advancement over immediate revenue generation. The lack of reported revenue in the trailing twelve months further contextualizes the company's position as an entity investing heavily in future potential rather than current commercial operations.
Financial Health
The company reports no revenue for the trailing twelve months, while posting a net income of $-37,723,000 and an EBITDA of $-38,295,000. The substantial gap between zero revenue and a net loss exceeding $37 million reveals a cost structure driven entirely by operational expenses, primarily research and development costs, rather than sales overhead. Free cash flow stands at $-30,363,876, indicating that the company is burning through cash reserves to fund its clinical trials and operational activities, which limits immediate financial flexibility but is expected in the biotech development phase. All three margin metrics—gross margin, operating margin, and profit margin—are reported at 0.0%, reflecting the absence of revenue and the inability to generate profit margins until commercial products are launched. On the balance sheet, the company holds $25.23M in cash against $912,000 in debt, resulting in a debt-to-equity ratio of 3.40 which suggests a leveraged position relative to equity but is offset by substantial liquid assets. The current ratio is 9.70, a figure that indicates strong short-term liquidity and the ability to meet obligations due within one year without difficulty. Return on Equity is -89.4% and Return on Assets is -42.2%, metrics that reveal management is currently destroying value on a per-share and per-asset basis due to heavy investment phases rather than profitability.
Valuation Assessment
The company exhibits a P/E Ratio (TTM) of N/A due to negative earnings, while the Forward P/E is listed at -4.14, implying that the market anticipates continued losses or a specific earnings trajectory that has not yet turned positive. The Price to Book ratio is 0.99, indicating that the market values the company slightly below its tangible book value, which is often seen in capital-intensive biotech firms where future intellectual property value is not fully captured on current balance sheets. The Price to Sales ratio is N/A and the EV/EBITDA is -0.04, suggesting that traditional valuation multiples based on sales or earnings are not applicable in the conventional sense for this stage of development. The stock has traded between a 52-Week High of $8.36 and a 52-Week Low of $2.20, with the current price context dependent on where it sits within this established volatility range relative to recent trading activity. With a Beta of 2.80, the stock demonstrates high price volatility relative to the broader market, moving with significantly greater intensity than the S&P 500 during periods of market fluctuation.
Growth & Income
Revenue Growth (YoY) and Earnings Growth (YoY) are both listed as N/A, precluding any analysis of growth rates as the company has not yet achieved commercial revenue to establish a historical growth trend. Since the company does not pay dividends, the dividend yield is N/A and the payout ratio is 0.0%, meaning all available earnings are theoretically available for reinvestment, though currently there are no earnings to distribute. As a non-dividend payer, the company reinvests its limited capital and cash reserves entirely into growth initiatives such as advancing the ATH-1105 pipeline asset for amyotrophic lateral sclerosis and other neurodegenerative treatments. The overall growth and income profile for LeonaBio, Inc. is defined by a reliance on capital markets for funding rather than organic revenue growth or dividend income, characteristic of pre-revenue biotechnology companies seeking to extend their cash runway through clinical trial progress.